How Pregnancy Can Prove the Potential of a Smartwatch

You are reading the web version of STAT Health Tech, a guide to how technology is transforming life sciences. Sign up and get this newsletter to your inbox every Tuesday and Thursday.

How Pregnancy Can Prove the Potential of a Smartwatch

Alex Hogan / STAT

iPhones, smartwatches, and other consumer devices are touted for their ability to detect illness and improve their health, but progress is slow to prove their value.Stephen Friend — Former Executive Merck, AppleWhen Sage Bionets — His latest organization is trying to change that. 4YouandMe, Has embarked on an ambitious effort to track data on about 1,000 pregnancies. This study collects a constant flow of hundreds of measurements from the device and regular reports on symptoms such as mood and malaise.


First and foremost, it is desirable to prove that we can reliably collect a large amount of data. But beyond that, researchers hope that some of these measurements can be used to explain the unique experience of an individual pregnancy and how much variability it has between individuals. .. The data may help develop better ways to predict and treat complications.

But for all possibilities in pregnancy alone, it was chosen as the target of opportunity. Dramatic physical changes that occur over a finite amount of time should create a rich data set for research that can prove once that a device can track health. Read Mario’s story here.


Faster A-fib diagnosis with AI

One of the challenges in diagnosing atrial fibrillation using a halter monitor is that arrhythmias take a long time to appear and may not appear in a short recording period. Massachusetts General Hospital And a heart care company Cardiolog Using a pile of halter records from six different diagnostic centers, we have developed an algorithm that can reliably predict A-fib in the first 24 hours to 2 weeks of recording. If confirmed by a prospective study, studies published in the European Heart Journal – Digital Health may lead to future systems that suggest which patients require longer monitoring to confirm the diagnosis. ..

Industry-sponsored research is likely to reach favorable conclusions

Cost-effectiveness research (data that insurers rely on to price medicines and devices) may show favorable cost-effectiveness when sponsored by drug, medical device, and biotechnology companies. Was high, a new analysis of BMJ discovered. For example, one-third of studies sponsored by pharmaceutical companies show better results than independently conducted studies. These usually use cost-effectiveness studies to justify higher prices for treatment.

Researchers analyzed more than 8,000 cost-effectiveness studies, one-third of which were sponsored by the company.

“Evidence strongly demonstrates the importance of sponsorship bias in cost-effective analysis. Bias is systemic and exists because it varies in degree across different diseases and study designs,” the study said. They are writing. STAT’s Ed Silverman has a complete story.

Transactions and Financing

News name

  • Named by President Biden Arati Prabhakar As his next top science advisor. Prabhakar used to be Defense Advanced Research Projects Agency Under the Obama administration.
  • Biopsy and cancer detection company Delphi diagnosis Appointment Eli Lilly Senior Vice President Jacob van Naden To that board.
  • Digital treatment company Kaia Health Named Christina Sierra With its Chief Technology Officer Simon Hayhurst Its Chief Product Officer. Lichti was formerly Chief Executive Officer of Benefits Software. ProperootsWhen Hayhurst He was Chief Product Officer at the agricultural analysis company Ceres Imaging.
  • Means healthEnables value-based care with technology and home health services, added Paimon Faraj As Chief Product Officer.He used to be a CPO OptumInsight..

What we are reading

Leave a Comment